Product
VMT-α-NET
1 clinical trial
5 indications
Indication
Neuroendocrine TumorsIndication
Lung Neuroendocrine TumorIndication
Neuroendocrine Tumor Grade 1Indication
Neuroendocrine TumorIndication
Neuroendocrine tumor of pancreasClinical trial
A Phase 1, First-in-human Clinical Trial of [212Pb] VMT-alpha-NET Using a Forward Dosimetric Planning Technique to Treat Refractory or Relapsed Neuroendocrine TumorsStatus: Active (not recruiting), Estimated PCD: 2026-11-20